All In Biotech

Drug Trial Radar · NCT00966355

Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding

RCT for the Effect of Early Administration of Vasoactive Substances When Combined With Endoscopic Treatment in Acute Gastro-esophageal Variceal Bleeds: Comparisons Among Terlipressin, Somatostatin, and Octreotide

Last checked: Nov 19, 2026Latest source record: Mar 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,034 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,034

Actual

Start

Sep 2006

Primary completion

May 2010

Study completion May 2010

Sponsor

Lead sponsor
Korea UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 26, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is performed to compare the efficacy of terlipressin, somatostatin, and octreotide in patients with variceal bleeding for the control of variceal bleeding in combination with endoscopic therapy.

Conditions

  • Variceal Bleeding, Cirrhosis

Interventions

  • TerlipressinDrug

    loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days

  • SomatostatinDrug

    loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days

  • OctreotideDrug

    loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 5-day Treatment Failure (Failure to Control Bleeding, Rebleeding, or Death)Time frame: 5 days after enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Anam Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.